This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, D.-G. Articles by Buchanan, K. D. Search for Related Content PubMed PubMed Citation Articles by Wang, D.-G. Articles by Buchanan, K. D.

Expression of the Apoptosis-Suppressing Gene BCL-2 in Pheochromocytoma is Associated with the Expression of C-MYC

Division of Metabolism and Endocrinology, School of Clinical Medicine (D.-G.W., C.F.J., K.D.B.), Molecular & Cell Biology Unit, School of Dentistry (J.J.M., K.V.P.), The Queen’s University of Belfast, and Sir George E. Clark Metabolic Unit (A.B.A.), Department of Endocrine Surgery (C.F.J.R.), Royal Victoria Hospital, Belfast, United Kingdom

Address all correspondence and requests for reprints to: Dr Da-Gong Wang, c/o Colin F. Johnston, Wellcome Research Laboratories, Department of Medicine, Institute of Clinical Science. Grosvenor Road, Belfast BT12 6BJ, United Kingdom.

It has become increasingly clear that deregulation of programmed cell death is a critical component in multistep tumorigenesis. Previous studies have demonstrated a high frequency of Bcl-2 expression in tumors arising from cells derived from the neural crest and in tumor cell lines of neural origin. The present investigation was undertaken to determine whether similar molecular events occur in human pheochromocytoma. With the aim of determining the potential role of apoptosis in the pathogenesis of this tumor, we assessed proto-oncogene Bcl-2 and c-myc protein products as well as Bcl-2 messenger RNA levels in a collection of such tumors. Western blot analysis revealed that such tumors expressed the 26 kDa Bcl-2 (5 of 8 cases) and the 64 kDa c-Myc (7 of 8 cases) proteins. Northern blot analysis detected the Bcl-2 transcripts in 6 of 8 tumors. Immunoperoxidase staining, using a monoclonal anti-Bcl-2 antibody, was positive in 18 (82%), including 5 malignant tumors, of the 22 specimens examined. This Bcl-2 immunoreactivity was seen in 14 of 18 (78%) sporadic tumors, including 2 that were extra-adrenal, and all familial tumors. Of the 22 tumor samples examined for c-Myc protein, 20 (91%) tumors were positive. Our results suggest that deregulation of programmed cell death may be a critical component in the multistep tumorigenesis of human pheochromocytoma. The genetic complementation of simultaneously deregulated Bcl-2 and c-myc may be implicated in this process.

This article has been cited by other articles:

				H. Kanauchi, N. Wada, D. G. Ginzinger, M. Yu, M. G. Wong, O. H. Clark, and Q.-Y. Duh Diagnostic and Prognostic Value of Fas and Telomeric-Repeat Binding Factor-1 Genes in Adrenal Tumors J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3690 - 3693. [Abstract] [Full Text] [PDF]

				M. Sarbia, C. Loberg, M. Wolter, J. Arjumand, H. Heep, G. Reifenberger, and H. E. Gabbert Expression of Bcl-2 and Amplification of c-myc Are Frequent in Basaloid Squamous Cell Carcinomas of the Esophagus Am. J. Pathol., October 1, 1999; 155(4): 1027 - 1032. [Abstract] [Full Text] [PDF]